Additional Utility of Pharmacogenomics (PGx) Panel Testing in a CYP2D6 Normal Metabolizer with a History of Breast Cancer

  • Michael Schuh Mayo School of Health Related Sciences
Keywords: Pharmacogenomics (PGx), Medication therapy management (MTM), Adverse drug reactions (ADRs), Factor V Leiden thrombophilia, Tamoxifen, CYP2D6, Comprehensive medication review (CMR), CYP2C19


Objective: To demonstrate the utility of pharmacogenomic (PGx) panel testing use versus single gene testing for a single indication. Panel testing may not only help further refine clinical decision making for the primary medical indication, it may uncover with one diagnostic test multiple PGx abnormalities, altering current and future therapy for other conditions.

Summary: Breast cancer patient presented to the pharmacist PGx service to discuss results and to help determine best guidance for post-surgical pain treatment. From the panel testing it was incidentally found the patient may be at higher clot risk from standard cancer prophylactic, hormone therapy as well as possible future cardiac therapy.

Conclusion: PGx panel testing may not only uncover potential medication related problems (MRPs) with the primary medical indication being tested, it may also refine therapy for other medical problems, resulting in avoidance of future MRPs and the health care costs associated with them. 


Article Type: Case Study


Download data is not yet available.
Received 2019-05-01
Accepted 2019-06-14
Published 2019-07-18
Pharmacy Practice & Practice-Based Research